Company intelligence / Profile preview
Peritech Pharma
- Ownership
- Private
- Development stage
- Other
01
Overview
Peritech Pharma’s lead product, PP-110—a novel over-the-counter anti-hemorrhoidal gel—demonstrated superior efficacy to Preparation-H in a pivotal clinical trial. The product has been commercialized in 24 countries. Another candidate, PP-120 for pruritus ani, completed Phase I testing and was planned for a pivotal study
- Therapeutic areas
- GastroenterologyDermatology
- Modalities
- Small moleculeGel-based drug delivery
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Peritech Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peritech Pharma.